Ri Liesner

12.0k total citations · 2 hit papers
123 papers, 6.6k citations indexed

About

Ri Liesner is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Ri Liesner has authored 123 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 29 papers in Genetics and 14 papers in Immunology. Recurrent topics in Ri Liesner's work include Hemophilia Treatment and Research (71 papers), Blood Coagulation and Thrombosis Mechanisms (48 papers) and Platelet Disorders and Treatments (45 papers). Ri Liesner is often cited by papers focused on Hemophilia Treatment and Research (71 papers), Blood Coagulation and Thrombosis Mechanisms (48 papers) and Platelet Disorders and Treatments (45 papers). Ri Liesner collaborates with scholars based in United Kingdom, United States and Germany. Ri Liesner's co-authors include Peter W. Collins, Kate Khair, Ian Hann, C. R. M. Hay, Samuel J. Machin, Ian Mackie, Marie Scully, Elizabeth Chalmers, David Keeling and Paul Harrison and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ri Liesner

120 papers receiving 6.4k citations

Hit Papers

Guidelines on the diagnosis and management of thrombotic ... 2012 2026 2016 2021 2012 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
    2012 553 citations Marie Scully, Beverley J. Hunt et al. British Journal of Haematology profile →
  2. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    2019 263 citations Guy Young, Ri Liesner et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ri Liesner United Kingdom 44 5.2k 1.6k 1.3k 630 531 123 6.6k
Paul Knöbl Austria 42 3.2k 0.6× 1.2k 0.7× 2.0k 1.5× 913 1.4× 678 1.3× 159 5.6k
Bertrand Godeau France 49 7.2k 1.4× 2.2k 1.4× 1.4k 1.0× 776 1.2× 256 0.5× 229 9.1k
Abdulgabar Salama Germany 32 2.4k 0.5× 770 0.5× 1.2k 0.9× 209 0.3× 341 0.6× 141 4.4k
Rob Fijnheer Netherlands 40 1.6k 0.3× 590 0.4× 1.2k 0.9× 384 0.6× 361 0.7× 137 4.4k
Francesco Rodeghiero Italy 53 8.6k 1.7× 2.3k 1.5× 1.2k 0.9× 550 0.9× 1.0k 2.0× 277 11.0k
Diane J. Nugent United States 43 4.8k 0.9× 848 0.5× 547 0.4× 193 0.3× 505 1.0× 181 6.8k
Paula Bolton‐Maggs United Kingdom 43 4.5k 0.9× 1.9k 1.2× 378 0.3× 136 0.2× 420 0.8× 158 6.7k
Lawrence A. Solberg United States 24 2.9k 0.6× 927 0.6× 423 0.3× 236 0.4× 521 1.0× 70 4.1k
Cindy Neunert United States 23 3.5k 0.7× 692 0.4× 423 0.3× 353 0.6× 139 0.3× 70 4.1k
Anand Padmanabhan United States 26 1.5k 0.3× 591 0.4× 885 0.7× 369 0.6× 282 0.5× 70 3.9k

Countries citing papers authored by Ri Liesner

Since Specialization
Citations

This map shows the geographic impact of Ri Liesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ri Liesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ri Liesner more than expected).

Fields of papers citing papers by Ri Liesner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ri Liesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ri Liesner. The network helps show where Ri Liesner may publish in the future.

Co-authorship network of co-authors of Ri Liesner

This figure shows the co-authorship network connecting the top 25 collaborators of Ri Liesner. A scholar is included among the top collaborators of Ri Liesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ri Liesner. Ri Liesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hart, Daniel P., Jayanthi Alamelu, Neha Bhatnagar, et al.. (2021). Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia. 27(6). 932–937. 17 indexed citations
2.
3.
Klukowska, Anna, et al.. (2018). Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A. Haemophilia. 24(4). 595–603. 12 indexed citations
4.
Mitchell, Michael, Michael Gattens, Kaan Kavaklı, et al.. (2018). Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency. Blood Coagulation & Fibrinolysis. 30(1). 34–41. 7 indexed citations
5.
Kruse‐Jarres, Rebecca, Michael U. Callaghan, Stacy E. Croteau, et al.. (2017). Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood. 130(Suppl_1). 89–89. 43 indexed citations
6.
7.
Collins, Peter W., Elizabeth Chalmers, Daniel P. Hart, et al.. (2014). Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 124(23). 3389–3397. 81 indexed citations
8.
Liesner, Ri, et al.. (2014). The value of the white precursor cell channel (WPC) on the Sysmex XN-1000 analyser in a specialist paediatric hospital. Journal of Clinical Pathology. 68(2). 161–165. 18 indexed citations
9.
Velzen, Alice S. van, Corien L. Eckhardt, Matthew Peters, et al.. (2013). Inhibitor eradication therapy in non-severe hemophilia A. Journal of Thrombosis and Haemostasis. 11. 207–207. 1 indexed citations
10.
Khair, Kate, et al.. (2013). Successful use of BPL Factor X concentrate in a child with severe factor X deficiency. 1(2). 8–10. 6 indexed citations
11.
Hay, C. R. M., Ben Palmer, Elizabeth Chalmers, et al.. (2011). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 117(23). 6367–6370. 140 indexed citations
12.
Chalmers, Elizabeth, Michael D. Williams, Janet Brennand, et al.. (2011). Guideline on the management of haemophilia in the fetus and neonate*. British Journal of Haematology. 154(2). 208–215. 56 indexed citations
13.
14.
Scully, Marie, Helen Yarranton, Ri Liesner, et al.. (2008). Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology. 142(5). 819–826. 257 indexed citations
15.
Khair, Kate & Ri Liesner. (2006). Bruising and bleeding in infants and children – a practical approach. British Journal of Haematology. 133(3). 221–231. 43 indexed citations
16.
Wilbourn, Barry, Paul Harrison, Ian Mackie, Ri Liesner, & Samuel J. Machin. (2003). Activation of platelets in whole blood by recombinant factor VIIa by a thrombin‐dependent mechanism. British Journal of Haematology. 122(4). 651–661. 9 indexed citations
17.
Liesner, Ri, et al.. (2003). Transient lupus anticoagulant: an unusual cause of bruising in children. Emergency Medicine Journal. 20(5). e6–e6. 15 indexed citations
18.
Liesner, Ri, et al.. (2000). Mutations in ELA2 encoding for neutrophil elastase are a frequent finding in sporadic but not familial severe congenital neutropenia.. UCL Discovery (University College London). 1 indexed citations
19.
Harrison, Paul, M. S. C. Robinson, Ian Mackie, et al.. (1999). Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis. Blood Coagulation & Fibrinolysis. 10(1). 25–32. 143 indexed citations
20.
Liesner, Ri, et al.. (1990). Malignant Mesenchymoma Associated with a Congenital Lung Cyst in a Child: Case Report and Review of the Literature. Pediatric Pathology. 10(5). 785–797. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Knöbl Breakdown of academic impact, for papers by Bertrand Godeau Breakdown of academic impact, for papers by Abdulgabar Salama Breakdown of academic impact, for papers by Rob Fijnheer Breakdown of academic impact, for papers by Francesco Rodeghiero Breakdown of academic impact, for papers by Diane J. Nugent Breakdown of academic impact, for papers by Paula Bolton‐Maggs Breakdown of academic impact, for papers by Lawrence A. Solberg Breakdown of academic impact, for papers by Cindy Neunert Breakdown of academic impact, for papers by Anand Padmanabhan
Rankless by CCL
2026